Observational studyBMC infectious diseases2025
Interim efficacy and safety analysis of the regimen containing delamanid in the treatment of multidrug resistant/rifampicin-resistant/extensively drug-resistant tuberculosis: a single-arm, prospective, monocentric, observational study.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04421495 (Safety and Effectiveness of Delamanid-containing Regimen for Treatment of Patients With Multidrug-resistant Tuberculosis in China), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Effectiveness of Delamanid-containing Regimen for Treatment of Patients With Multidrug-resistant Tuberculosis in China
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant, rifampicin-resistant, and extensively drug-resistant tuberculosis (MDR-TB/RR-TB/XDR-TB) present significant treatment challenges, requiring effective and safe therapeutic regimens. This study aims to assess the efficacy and safety of a 24-week regimen that includes Delamanid (Dlm) for patients with these resistant forms of tuberculosis.
methodsThis was a single-arm, prospective, monocentric, observational trial. From June 2020 to January 2023, 29 patients meeting the inclusion criteria were selected from Hangzhou Red Cross Hospital. These patients received a treatment regimen that included Dlm. Data were collected on patient demographics, sputum culture conversion rates, and pulmonary lesion changes after 24 weeks. Additionally, adverse events (AEs) that occurred during treatment were recorded and analyzed.
resultsOut of the 29 patients, 26 completed the initial 24-week intensive phase treatment, with 2 patients withdrawing due to adverse reactions and 1 patient being lost to follow-up. The cohort included 11 MDR-TB, 3 RR-TB, and 12 XDR-TB patients. All 26 patients who were sputum culture-positive at baseline achieved culture conversion within the 24-week treatment period, resulting in a 100% conversion rate. Conversion was confirmed in all patients tested on solid media (18/18) and liquid media (8/8). The median time to sputum culture conversion was 34 days for solid and 70 days for liquid media. Imaging showed significant pulmonary lesion absorption in 21 cases and partial absorption in 3 cases. Improvements in pulmonary cavities were noted in 15 patients. A total of 108 AEs were reported, with the most common being liver function abnormalities (61.5%), anemia (50%), and leukopenia (42.3%). No serious AEs or deaths occurred, and 24 patients (92.3%) had favorable outcomes.
conclusionsThe regimen containing Delamanid during the initial 24 weeks intensive phase of treatment demonstrated high efficacy in achieving sputum culture conversion and showed an acceptable safety profile in MDR-TB/RR-TB/XDR-TB patients, offering a valuable treatment option for this difficult-to-treat population.
trial registrationIt registered in ICH GCP-US Clinical Trials Registry and the registration number is NCT04421495 and date of registration was June 9, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.